BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25577710)

  • 1. Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy.
    Gao Z; Hurst WJ; Hall D; Hartung R; Reynolds W; Kang J; Nagorny R; Hendrix JA; George PG
    Bioorg Med Chem; 2015 Feb; 23(3):429-38. PubMed ID: 25577710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-yl)phenyl] amide as histamine H(3) receptor antagonist for the treatment of depression.
    Gao Z; Hurst WJ; Czechtizky W; Hall D; Moindrot N; Nagorny R; Pichat P; Stefany D; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6269-73. PubMed ID: 24139584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, characterization, and biological assessment of the four stereoisomers of the H(3) receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3']bipyrrolidinyl-1'-yl)phenyl]benzamide.
    Gao Z; Hurst WJ; Guillot E; Nagorny R; Pruniaux MP; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4044-7. PubMed ID: 23769643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using electrophysiology and in silico three-dimensional modeling to reduce human Ether-à-go-go related gene K(+) channel inhibition in a histamine H3 receptor antagonist program.
    Davenport AJ; Möller C; Heifetz A; Mazanetz MP; Law RJ; Ebneth A; Gemkow MJ
    Assay Drug Dev Technol; 2010 Dec; 8(6):781-9. PubMed ID: 21133680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
    Gao Z; Hurst WJ; Czechtizky W; Francon D; Griebel G; Nagorny R; Pichat P; Schwink L; Stengelin S; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6141-5. PubMed ID: 24076172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
    Levoin N; Labeeuw O; Calmels T; Poupardin-Olivier O; Berrebi-Bertrand I; Lecomte JM; Schwartz JC; Capet M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5378-83. PubMed ID: 21802950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.
    Sadek B; Schwed JS; Subramanian D; Weizel L; Walter M; Adem A; Stark H
    Eur J Med Chem; 2014 Apr; 77():269-79. PubMed ID: 24650714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity.
    Kuder KJ; Stachnik M; Schunack W; Szymańska E; Kieć-Kononowicz K
    Med Chem; 2014; 10(6):588-99. PubMed ID: 24047214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-imidazole histamine H3 ligands, part IV: SAR of 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives.
    Frymarkiewicz A; Walczyński K
    Eur J Med Chem; 2009 Apr; 44(4):1674-81. PubMed ID: 18990469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
    Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
    J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel imidazole-based histamine H3 antagonists.
    Jablonowski JA; Ly KS; Bogenstaetter M; Dvorak CA; Boggs JD; Dvorak LK; Lord B; Miller KL; Mazur C; Wilson SJ; Lovenberg TW; Carruthers NI
    Bioorg Med Chem Lett; 2009 Feb; 19(3):903-7. PubMed ID: 19119007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
    Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
    J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
    Zhao C; Sun M; Bennani YL; Miller TR; Witte DG; Esbenshade TA; Wetter J; Marsh KC; Hancock AA; Brioni JD; Cowart MD
    J Med Chem; 2009 Aug; 52(15):4640-9. PubMed ID: 19588934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.
    Kumar A; Pasam VR; Thakur RK; Singh M; Singh K; Shukla M; Yadav A; Dogra S; Sona C; Umrao D; Jaiswal S; Ahmad H; Rashid M; Singh SK; Wahajuddin M; Dwivedi AK; Siddiqi MI; Lal J; Tripathi RP; Yadav PN
    J Med Chem; 2019 May; 62(9):4638-4655. PubMed ID: 30998358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Imidazole Histamine H3 Ligands. Part VI. Synthesis and Preliminary Pharmacological Investigation of Thiazole-Type Histamine H3-Receptor Antagonists with Lacking a Nitrogen Nucleus in the Side Chain.
    Guryn R; Staszewski M; Kopczacki P; Walczyski K
    Med Chem; 2016; 13(1):65-76. PubMed ID: 27220560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.
    Procopiou PA; Ancliff RA; Bamford MJ; Browning C; Connor H; Davies S; Fogden YC; Hodgson ST; Holmes DS; Looker BE; Morriss KM; Parr CA; Pickup EA; Sehmi SS; White GV; Watts CJ; Wilson DM; Woodrow MD
    J Med Chem; 2007 Dec; 50(26):6706-17. PubMed ID: 18052318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New lead elements for histamine H
    Espinosa-Bustos C; Frank A; Arancibia-Opazo S; Salas CO; Fierro A; Stark H
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2890-2893. PubMed ID: 30025902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs.
    Lipani L; Odadzic D; Weizel L; Schwed JS; Sadek B; Stark H
    Eur J Med Chem; 2014 Oct; 86():578-88. PubMed ID: 25218907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.
    Brown DG; Bernstein PR; Griffin A; Wesolowski S; Labrecque D; Tremblay MC; Sylvester M; Mauger R; Edwards PD; Throner SR; Folmer JJ; Cacciola J; Scott C; Lazor LA; Pourashraf M; Santhakumar V; Potts WM; Sydserff S; Giguère P; Lévesque C; Dasser M; Groblewski T
    J Med Chem; 2014 Feb; 57(3):733-58. PubMed ID: 24410637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.
    Zeng Q; Rosenblum SB; Yang Z; Jiang Y; McCormick KD; Aslanian RG; Duguma L; Kozlowski JA; Shih NY; Hey JA; West RE; Korfmacher WA; Berlin M; Boyce CW
    Bioorg Med Chem Lett; 2013 Nov; 23(21):6001-3. PubMed ID: 24050887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.